Stroke & cognition in surgical aortic stenosis

中风

• 批准号: 7480252
• 负责人: Thomas F. Floyd
• 金额: $ 76.77万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-09-01 至 2012-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7480252
• 关键词: Acceleration; Accounting; Acute; Adult; Age; Aging; Anatomy; Anemia; Aorta; Aortic Valve Stenosis; Biological Markers; Blood Vessels; Brain; Cannulas; Cardiac Surgery procedures; Cardiopulmonary Bypass; Cerebral Infarction; Cerebrum; Clinical; Clinical Trials; Cognition; Cognitive; Consensus; Control Groups; Coronary; Coronary Artery Bypass; Databases; Dementia; Deterioration; Devices; Diagnosis; Diffusion; Diffusion Magnetic Resonance Imaging; Disease; Documentation; Early Diagnosis; Early Intervention; Elements; Embolism; End Point; Etiology; Evaluation; Event; Failure; Foundations; Frequencies; Future; General Population; Goals; Guidelines; Image; Impaired cognition; Incidence; Indium; Intervention; Investigation; Ischemia; Lesion; Measurement; Measures; Medical Surveillance; Modems; Neurologic; Neurologist; Neuroprotective Agents; Numbers; Operative Surgical Procedures; Outcome; Pathogenesis; Patients; Performance; Phase; Phase II Clinical Trials; Population; Population Study; Postoperative Period; Procedures; Process; Prospective Studies; Pump; Range; Rate; Reporting; Research Personnel; Risk; Role; Secondary to; Series; Severities; Stroke; Subgroup; Testing; Therapeutic; Time; United States; Validation; Vascular Dementia; Week; Weight; aged; aortic valve; cognitive function; concept; cost; cost efficient; design; disability; efficacy trial; improved; innovation; ischemic lesion; mortality; neuroprotection; programs; success; treatment effect; white matter

DESCRIPTION (provided by applicant): Background: Calcific aortic stenosis(AS) is the leading valvular disease in the United States. The number of patients with this diagnosis and requiring aortic valve replacement(AVR) is growing rapidly with the aging of our population. Emboli are implicated in most strokes and in postopertive cognitive dysfunction(POCD) after heart surgery. Patients presenting for AVR for AS define a subgroup at "extraordinary" risk(10%) for postoperative stroke, and 40% suffer multiple cerebral embolic events. These patients also are at risk for POCD and or vascular cognitive impairment secondary to these multiple cerebral infarctions in the short- term, and may be at risk for an acceleration toward long-term vascular dementia. This is a key population in which to study not only the pathogenesis of stroke and POCD, but also one in which the success or failure of neuroprotective interventions may be efficiently demonstrable. Aims: Aim-1) To determine the incidence the outcomes of stroke and cerebral transient ischemic events in an aged population, after AVR for AS; Aim-2) To determine the validity of a surrogate imaging biomarkertor postoperative cerebral ischemic events after AVR, using pre and postoperative Diffusion-Weighted MRI(DWI); Aim-3)Jo determine the change in cognitive performance in the aged patient after AVR for AS as compared to age/disease matched controls over time. Relevance:Post-surgical stroke portends a 5-10-fold increase in early mortality, while 69% suffer severe disability. Advances in the treatment of patients in the general stroke population, where early diagnosis, and an organized approach to early intervention has profoundly impacted outcome. Oddly, an organized approach to stroke surveillance after heart surgery, in a "captured" population, where the occurrence of stroke is not only frequent but predictable, rarely exists. (The 5-fold variance in the reported incidence of stroke after AVR is very telling.) Conversely, with the opportunity for close surveillance, benefits of rapid intervention/neuroprotection could reasonably be expected to surpass those seen in the general population. Neuroprotection trials have failed at an alarming rate due to inadequate design. A key element in designing properly powered studies is knowing accurately the frequency of the outcome to be studied. An accurate accounting of the risk of two important ischemic endpoints, stroke and POCD, will serve as a foundation for future trials. Validation of a potential imaging surrogate for stroke after AVR, DWI-MRI lesions, may allow for the efficient conduct of "proof of concept" studies in much smaller populations. Advanced imaging approaches paired with detailed cognitive analyses may allow us to deepen our understanding of the pathogenesis of POCD. Finally, the study database will allow us to closely examine the long-term risks for cognitive impairment & dementia from embolic processes during heart surgery..

描述（由申请人提供）：背景：钙化性主动脉瓣狭窄（AS）是美国的主要瓣膜疾病。随着我国人口老龄化，诊断为该疾病并需要进行主动脉瓣置换术（AVR）的患者数量正在迅速增长。栓塞与大多数中风和心脏手术后的术后认知功能障碍（POCD）有关。因主动脉瓣置换术治疗主动脉瓣狭窄的患者定义为术后卒中风险“非常高”的亚组（10%），40%的患者发生多种脑栓塞事件。这些患者在短期内也有继发于这些多发性脑梗死的POCD和/或血管性认知障碍的风险，并且可能有加速发展为长期血管性痴呆的风险。这是一个关键的人群，不仅研究中风和POCD的发病机制，而且也是一个神经保护干预的成功或失败可能是有效的证明。目的：目的-1）确定老年人群中主动脉瓣置换术后卒中和短暂性脑缺血事件的发生率和结局;目的-2）使用术前和术后弥散加权MRI（DWI）确定替代成像标记物对主动脉瓣置换术后脑缺血事件的有效性;目的-3）确定与年龄/疾病匹配的对照组相比，老年患者接受主动脉瓣置换术治疗主动脉瓣狭窄后认知能力随时间的变化。相关性：手术后中风预示着早期死亡率增加5-10倍，而69%的患者患有严重残疾。在一般卒中人群中，早期诊断和有组织的早期干预方法对患者的治疗进展产生了深远的影响。奇怪的是，在“捕获”人群中，心脏手术后卒中监测的有组织方法很少存在，其中卒中的发生不仅频繁，而且可预测。(The AVR后报告的卒中发生率的5倍变化非常有说服力。）相反，随着密切监测的机会，快速干预/神经保护的益处可以合理地预期超过在一般人群中观察到的益处。由于设计不当，神经保护试验以惊人的速度失败。设计适当把握度研究的一个关键因素是准确了解要研究的结果的频率。对两个重要的缺血性终点（卒中和POCD）风险的准确描述将作为未来试验的基础。验证AVR后卒中的潜在成像替代物，DWI-MRI病变，可能允许在更小的人群中有效进行“概念验证”研究。先进的成像方法与详细的认知分析相结合，可以加深我们对POCD发病机制的理解。最后，该研究数据库将使我们能够仔细检查心脏手术期间栓塞过程导致认知障碍和痴呆的长期风险。